Drug intelligence / Profile preview

HP828-101

Development stage: Unknown
Lead developer: Healthpoint
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

HP828-101 is an investigational topical ointment developed for dermatological use, specifically evaluated for its potential in treating pressure ulcers and for its skin irritation profile. Clinical studies have assessed the cumulative irritation potential of HP828-101 ointment compared to controls such as Johnson's baby oil and sodium lauryl sulfate, as well as its efficacy in the management of pressure ulcers. The precise mechanism of action has not been disclosed in public sources. The drug was developed by Healthpoint.

Other names: 828 Ointment

Beyond the preview

Go deeper on HP828-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HP828-101.

Explore the full profile